Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Presenting at Proactive Investors Investor Forum

25th Sep 2012 09:30

RNS Number : 0657N
Sphere Medical Holding plc
25 September 2012
 

 

 

For Immediate Release

25 September 2012

 

 

Sphere Medical Holding plc

 

Sphere Medical to present at Proactive Investors One2One Investor Forum on Thursday 27 September

 

Cambridge, UK, 25 September 2012: Sphere Medical Holding plc (AIM: SPHR.L, the "Company"), a leading developer of innovative monitoring and diagnostic devices for the critical care setting, will present its investment story to investors at the Proactive Investors One2One Investor Forum on Thursday 27th September 2012 from 6.00pm.

Stuart Hendry, Chief Executive Officer, and Matthew Hall, Chief Financial Officer will present the Company's strategy and recent progress plus upcoming newsflow and be available for Q&A. The event will be held at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair, London W1J 5EB.

The event is open to private investors, private client brokers, fund managers, financial institutions, hedge funds, buy & sell side analysts and journalists. Further information can be found at: http://www.proactiveinvestors.co.uk/register/event_details/160 

 

For further information, please contact:

 

Sphere Medical Holding plc

Tel: +44 (0)1223 875222

Dr Stuart Hendry, Chief Executive Officer

Matthew Hall, Chief Financial Officer

Peel Hunt LLP

Tel: +44 (0) 20 7418 8900

James Steel

Dr Vijay Barathan

M:Communications

Mary-Jane Elliott, Amber Bielecka, Hollie Vile

Tel: +44 (0) 20 7920 2333

[email protected]

 

About Sphere Medical

Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's Proxima and Cardiopulmonary Bypass devices deliver real time analysis of blood gases, electrolytes, glucose and drug levels with laboratory accuracy, at the patient's bedside. Globally over 240 million blood gas and electrolyte tests are carried out on patients every year in critical care and there is an unmet need for monitoring products that are small, simple to use and cost effective with improved functionality. Sphere Medical's products can be used in a wide range of medical applications enabling faster clinical decision making and consequently improved patient outcomes, whilst also reducing costs for healthcare payers.

Sphere Medical is headquartered in Cambridge, UK and employs around 60 people. The Company has existing commercial partnerships with the leading global medical device companies.

For further information, please visit www.spheremedical.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAMMGZLRKZGZZG

Related Shares:

Sphere Medical Holding
FTSE 100 Latest
Value8,415.25
Change0.00